Global Prostate Cancer Therapeutics Strategic Business Report 2018-2022 - Rising Incidence of Prostate Cancer: Cornerstone for the Market - ResearchAndMarkets.com

DUBLIN--()--The "Prostate Cancer Therapeutics - Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering.

The report provides separate comprehensive analytics for the US, Canada, Europe, and Rest of World. Annual estimates and forecasts are provided for the period 2015 through 2022. Also, a six-year historic analysis is provided for these markets.

This report analyzes the worldwide markets in US$ Million by the following Segments:

  • Hormone Therapy
  • Other Therapies

The report profiles 76 companies including many key and niche players such as:

  • AbbVie, Inc. (USA)
  • Allergan plc (Ireland)
  • Amgen, Inc. (USA)
  • Astellas Pharma, Inc. (Japan)
  • AstraZeneca Plc. (UK)
  • Bayer AG (Germany)
  • Bristol-Myers Squibb Company (USA)
  • Debiopharm Group (Switzerland)
  • Dendreon Pharmaceuticals LLC (USA)
  • Endo Pharmaceuticals Inc. (USA)
  • F. Hoffmann-La Roche Ltd. (Switzerland)
  • Genentech Inc. (USA)
  • GlaxoSmithKline Plc. (UK)
  • Janssen Biotech, Inc. (USA)
  • Myovant Sciences Ltd. (UK)
  • Novartis AG (Switzerland)
  • Pfizer, Inc. (USA)
  • Progenics Pharmaceuticals, Inc. (USA)
  • Sanofi S.A. (France)
  • Spectrum Pharmaceuticals, Inc. (USA)
  • Takeda Pharmaceutical Company Limited (Japan)
  • TOLMAR Pharmaceuticals, Inc. (USA)

Key Topics Covered

1. INDUSTRY OVERVIEW

  • An Insight in the Global Market for Prostate Cancer Diagnostics and Therapeutics
  • Rising Incidence of Prostate Cancer: Cornerstone for the Market
  • Current & Future Analysis
  • Developed Markets: Traditional Revenue Contributors
  • Developing Countries Turbo Charge Future Market Growth
  • An Insight into the Castration-Resistant Prostate Cancer Therapeutics Market
  • Market Outlook & Trends
  • Zytiga (Abiraterone acetate): The Market Leader
  • Select Drugs that Received Approval for Castration-Resistant Prostate Cancer (CRPC)

2. PRODUCT OVERVIEW

3. DRUG APPROVALS AND CLINICAL STUDIES

  • Janssen Biotech Receives Approval for Erleada
  • Janssen Pharmaceutical Bags Approval for ZYTIGA for Metastatic High-Risk CSPC
  • Janssen Biotech Submits Supplemental NDA for ZYTIGA to Treat Early Stage Metastatic Prostate Cancer
  • Bavarian Nordic to Discontinue Phase 3 PROSPECT Study on mCRPC
  • Bavarian Nordic Announces Phase 2 Clinical Trial of PROSTVAC
  • OncBioMune Pharmaceuticals Offers Latest Clinical Data of ProscaVax
  • Pfizer and Astellas Pharma Announces Phase 3 PROSPER Trial Results of XTANDI

4. PRODUCT LAUNCHES

  • QIAGEN Commercializes AdnaTest Prostate Cancer Panel AR-V7 for Research Use
  • GenomeDx Biosciences Launches Decipher Biopsy Test for Prostate Cancer
  • Profound Medical and Siemens Sign Agreement to Launch TULSA- PROTM System

5. RECENT INDUSTRY ACTIVITY

  • Valeant Pharmaceuticals International to Divest Dendreon Pharmaceuticals to Sanpower Group
  • AbbVie Enters into Immuno-Oncology Research Collaboration with Harpoon Therapeutics
  • AstraZeneca Inks Pact with TerSera Therapeutics
  • Bristol-Myers Squibb and Clovis Oncology Ink a Broad Clinical Collaboration Agreement
  • J&J Expands Market for Zytiga
  • Telix Pharmaceuticals Completes Product Collaboration and Purchase Option Agreement with Atlab Pharma
  • UCLA Sells Xtandi Rights to Royalty Pharma

6. FOCUS ON SELECT GLOBAL PLAYERS

7. GLOBAL MARKET PERSPECTIVE

  • Total Companies Profiled: 76 (including Divisions/Subsidiaries 84)
    • The United States (47)
    • Canada (6)
  • Japan (4)
  • Europe (23)
    • France (5)
    • Germany (3)
    • The United Kingdom (5)
    • Rest of Europe (10)
  • Asia-Pacific (Excluding Japan) (4)

For more information about this report visit https://www.researchandmarkets.com/research/mc3hkg/global_prostate?w=4

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Prostate Cancer Drugs

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Prostate Cancer Drugs